Kevzara

Sarilumab, the active ingredient in Kevzara, is an IL‑6 receptor antagonist presented as a subcutaneous solution for subcutaneous use. It is indicated for the treatment of rheumatoid arthritis and for hospitalized COVID‑19 patients who require supplemental oxygen. The medication works by binding both soluble and membrane‑bound IL‑6 receptors, thereby reducing inflammatory signaling.

GNH USA supplies Kevzara as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide, ensuring reliable cold‑chain logistics, regulatory compliance and timely delivery.

Kevzara (sarilumab) acts on the interleukin‑6 signaling pathway and is used in inflammatory and immune‑mediated conditions.

- Rheumatoid arthritis: improves joint symptoms, reduces inflammation and slows structural damage. - COVID‑19 (hospitalized patients requiring supplemental oxygen): may lower the risk of progression to mechanical ventilation and death. - Severe rheumatoid arthritis refractory to conventional therapy: provides an alternative biologic treatment option.

Common Side Effects: - Injection site reactions: redness, swelling, or pain at the injection site. - Neutropenia: lowered neutrophil count, increasing infection risk. - Elevated liver enzymes: mild increases in ALT or AST. - Upper respiratory tract infection: symptoms such as sore throat or nasal congestion. - Headache: mild to moderate intensity. - Diarrhea: loose stools, usually transient.

Serious or Rare Side Effects: - Serious infections: including bacterial, fungal, or opportunistic infections. - Hypersensitivity reactions: rash, urticaria, or anaphylaxis. - Gastrointestinal perforation: rare but potentially life‑threatening. - Severe liver injury: marked elevation of liver enzymes or hepatitis. - Severe neutropenia or thrombocytopenia: markedly low blood cell counts. - Cytokine release syndrome: systemic inflammatory response after dosing.

Kevzara requires careful monitoring and patient assessment before and during therapy.

- Monitor blood counts: regular CBC to detect neutropenia or thrombocytopenia. - Monitor liver function: periodic ALT/AST testing for hepatic effects. - Assess for infections: screen for active infections before each dose. - Evaluate hypersensitivity: check for prior allergic reactions to biologics. - Use caution in patients with active tuberculosis or chronic infections. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kevzara may interact with other immunomodulatory agents and vaccines.

Major Interactions (Avoid): - Live vaccines: concurrent use can cause uncontrolled infection. - Strong immunosuppressants (e.g., high‑dose azathioprine): may markedly increase infection risk.

Moderate Interactions (Monitor Closely): - Other biologic agents (e.g., TNF inhibitors): combined use may elevate infection susceptibility. - CYP450 inducers (e.g., rifampin): may modestly reduce sarilumab efficacy. - Anticoagulants (e.g., warfarin): monitor INR as inflammation changes can affect clotting.